4D Molecular Therapeutics, Inc. (FDMT) Operating Margin
- Operating margin · 12 months: Value -214.24%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -214.24% | Operating income / revenue. Period ending 2026-06-30. $-197.12M ÷ $92.01M × 100 ≈ -214.24% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -197.12M USD | Operating Income (Loss) |
| Revenue | 92.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-197.12M | $92.01M | (m) | (m) | (m) | -214.24% |
| 2026-03-31 | $-179.55M | $88.24M | (m) | (m) | (m) | -203.47% |
| 2025-12-31 | $-159.55M | $85.21M | (m) | (m) | (m) | -187.24% |
| 2025-09-30 | $-230.38M | $120.00K | (m) | (m) | (m) | -191982.50% |
| 2025-06-30 | $-220.33M | $33.00K | (m) | (m) | (m) | -667654.55% |
| 2025-03-31 | $-203.33M | $23.00K | (m) | (m) | (m) | -884026.09% |
| 2024-12-31 | $-187.84M | $37.00K | (m) | (m) | (m) | -507678.38% |
| 2024-09-30 | $-168.38M | $17.00K | (m) | (m) | (m) | -990447.06% |
| 2024-06-30 | $-131.22M | $20.22M | (m) | (m) | (m) | -649.02% |
| 2024-03-31 | $-120.90M | $20.45M | (m) | (m) | (m) | -591.10% |
| 2023-12-31 | $-112.87M | $20.72M | (m) | (m) | (m) | -544.65% |
| 2023-09-30 | $-104.94M | $21.99M | (m) | (m) | (m) | -477.22% |
| 2023-06-30 | $-117.45M | $2.29M | (m) | (m) | (m) | -5140.26% |
| 2023-03-31 | $-113.75M | $2.21M | (m) | (m) | (m) | -5151.54% |
| 2022-12-31 | $-110.03M | $3.13M | (m) | (m) | (m) | -3516.52% |
| 2022-09-30 | $-106.08M | $1.97M | (m) | (m) | (m) | -5373.66% |
| 2022-06-30 | $-102.24M | $2.84M | (m) | (m) | (m) | -3600.11% |
| 2022-03-31 | $-81.41M | $17.26M | (m) | (m) | (m) | -471.77% |
| 2021-12-31 | $-71.33M | $18.04M | (m) | (m) | (m) | -395.46% |
| 2021-09-30 | $-66.99M | $16.97M | (m) | (m) | (m) | -394.78% |
| 2021-06-30 | $-52.15M | $23.02M | (m) | (m) | (m) | -226.49% |
| 2021-03-31 | $-59.70M | $11.95M | (m) | (m) | (m) | -499.49% |
| 2020-12-31 | $-56.66M | $13.36M | (m) | (m) | (m) | -424.04% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-50.76M | $6.96M | (m) | (m) | (m) | -729.37% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |